ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinic... (ce-President MedicalTechnologies. More ...)

ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies

Date:1/18/2008

ce-President, Medical Technologies. "More worryingly, it adds weight to the argument that a second wave of vCJD may be on the horizon with these individuals exhibiting much longer incubation times for the disease."

This latest data and continuation of clinical evaluation of the P-Capt(R) filter by the Irish and UK National Blood Services, in combination with this latest news all point to a likely adoption of the P-Capt(R) filter in 2008. "We are greatly encouraged by the completion of the clinical evaluation on volunteers," stated Ms. Iwona Walicka, Project Manager, MacoPharma. "Both MacoPharma and ProMetic are now gearing up for what we expect to be a watershed year for the product."

Notes for Editors

P-Capt(R) Filter

The P-Capt(R) filter removes, to the limit of detection, the infectivity that is naturally present in blood during infections by Transmissible Spongiform Encephalopathies ("TSEs"), such as variant Creutzfeldt-Jakob disease ("vCJD") and it reduces the risk of transmission of infection by contaminated blood.

Variant Creutzfeldt-Jakob Disease

Variant Creutzfeldt-Jakob disease ("vCJD") is characterized by the accumulation of large deposits in the brain and the nervous system of the misfolded prion protein. The resulting damage causes sponge-like holes to appear in the brain causing a fatal degenerative CNS disorder. Such abnormal prion proteins may be sufficient to transmit the disease. It is now thought that all the population is susceptible to vCJD, irrespective of genetic make-up. vCJD was initially transmitted to humans by the consumption of BSE contaminated meat, but a secondary route of transmission by the transfusion of blood units from asymptomatic vCJD individuals threatens to increase the prevalence of the fatal disease. Although the first incidence of vCJD appears to have peaked, scientists still remain concerned over the potential of a second longer incubation and bigger peak and caution vigilanc
'/>"/>

3

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results

Post Your Comments:

ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinic...(ce-President MedicalTechnologies. More ...)